Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 9/20 | 1.00 |
| ▸ | CACNA1B | Q00975 | 9/20 | 1.00 |
| ▸ | CACNB1 | Q02641 | 9/20 | 1.00 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.73 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.65 |
| ▸ | CNR1 | P21554 | 9/20 | 0.65 |
| ▸ | CNR2 | P34972 | 9/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5544073 | 0.89 | CACNA2D1 (1.00) | CACNA2D1CACNA1BCACNB1CACNA1GCACNA1C | |
| SCHEMBL5544042 | 0.87 | CACNA2D1 (1.00) | CACNA2D1CACNA1BCACNB1CACNA1GCACNA1C | |
| SCHEMBL5547482 | 0.86 | CACNA2D1 (1.00) | CACNA2D1CACNA1BCACNB1CACNA1GCACNA1C | |
| SCHEMBL5265544 | 0.84 | CACNA1G (1.00) | CACNA2D1CACNA1BCACNB1CACNA1GCACNA1C | |
| SCHEMBL5547406 | 0.84 | CACNA2D1 (1.00) | CACNA2D1CACNA1BCACNB1CACNA1GCACNA1C | |
| SCHEMBL5541405 | 0.84 | CACNA2D1 (1.00) | CACNA2D1CACNA1BCACNB1CACNA1GCACNA1C | |
| SCHEMBL5541470 | 0.81 | CACNA2D1 (1.00) | CACNA2D1CACNA1BCACNB1CACNA1GCACNA1C | |
| SCHEMBL6505599 | 0.80 | CACNA2D1 (0.67) | CACNA2D1CACNA1BCACNB1CACNA1GCACNA1C | |
| SCHEMBL5541451 | 0.79 | CACNA2D1 (1.00) | CACNA2D1CACNA1BCACNB1CACNA1GCACNA1C | |
| SCHEMBL5543965 | 0.78 | CACNA2D1 (0.77) | CACNA2D1CACNA1BCACNB1CACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050227999-A1 | Diarylamine derivatives as calcium channel blockers | NEUROMED TECHNOLOGIES INC. | 2005-10-13 | — | — | US | claimed |
| EP-1745042-A1 | DIARYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | Neuromed Pharmaceuticals, Ltd. (CA) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005097779-A1 | DIARYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2005-10-20 | — | — | WO | disclosed |
| US-20050227999-A1 | Diarylamine derivatives as calcium channel blockers | NEUROMED TECHNOLOGIES INC. | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227999-A1 | Diarylamine derivatives as calcium channel blockers | ORAI1, CACNA1D, CACNA1C | CACNA2D1 51/4885CACNA1B 4/4885CACNB1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.